Outcome after treatment of detrusor-sphincter dyssynergia by temporary stent.
OBJECTIVE
To evaluate follow-up treatments used after treatment of detrusor-sphincter dyssynergia (DSD) by a temporary urethral sphincter stent.


METHODS
Between February 1994 and June 2003, 147 men with a mean age of 41.3+/-14.4 years were treated by temporary urethral stent inserted across the external sphincter for DSD. The underlying neurologic disease was quadriplegia in 85 cases, multiple sclerosis in 24 cases and paraplegia in 21 cases. A Nissenkorn (Bard) stent was used in 130 cases and a Diabolo (Porgès) stent was used in 17 cases. All patients were either unable to or they refused to perform intermittent self-catheterization. DSD was demonstrated by urodynamic studies in every case.


RESULTS
The mean duration of temporary stenting was 10.15+/-16.07 months. After temporary stenting, 92 patients were treated by permanent stent (Ultraflex, Boston Scientifics), 7 started intermittent self-catheterization, 12 had repeated changes of the temporary stent, 4 had an indwelling catheter, 3 underwent cystectomy with non-continent diversion, 2 were treated by endoscopic sphincterotomy, 1 was treated by bladder neck incision, 1 was treated by neuromodulation and 1 was treated by cystostomy. Fifteen patients were lost to follow-up. Two patients died during follow-up (not related to DSD).


CONCLUSIONS
After treatment of DSD by a temporary urethral sphincter stent, 70.7% of patients subsequently require a permanent urethral sphincter stent. This period allows selection of patients unlikely to benefit from permanent urethral sphincter stent.
Gamé
X
X
Service d'Urologie, Groupe Hospitalier Pitié-Salpétrière, Paris, France.
Chartier-Kastler
E
E
Ayoub
N
N
Even-Schneider
A
A
Richard
F
F
Denys
P
P
D000328:Adult; D002404:Catheterization / Q000295:instrumentation / Q000379:methods / Q000706:statistics & numerical data; D002408:Catheters, Indwelling / Q000009:adverse effects / Q000706:statistics & numerical data; D015653:Cystectomy; D003559:Cystostomy; D004724:Endoscopy / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications; D010243:Paralysis / Q000150:complications; D011183:Postoperative Complications / Q000209:etiology / Q000503:physiopathology; D012189:Retrospective Studies; D013118:Spinal Cord Diseases / Q000150:complications*; D013119:Spinal Cord Injuries / Q000150:complications; D015607:Stents / Q000009:adverse effects / Q000706:statistics & numerical data*; D016896:Treatment Outcome; D014521:Urethra / Q000294:innervation / Q000503:physiopathology / Q000601:surgery*; D001743:Urinary Bladder / Q000294:innervation / Q000503:physiopathology / Q000601:surgery*; D001750:Urinary Bladder, Neurogenic / Q000503:physiopathology / Q000601:surgery*; D013521:Urologic Surgical Procedures, Male / Q000295:instrumentation* / Q000379:methods